Anil Kapur

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
San Francisco, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Daniel Calkins, Attorney in Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Anil Kapur

Form 4 holding EVP, Corp Strategy & CCO

GERON CORP

Security class
Common Stock
Shares / value
0
Estimated value
$0
Report date
10 Jun 2024
Price
$4.64
Ownership
Direct
Form 4 holding EVP, Corp Strategy & CCO

GERON CORP

Security class
Stock Option (right to buy)
Shares / value
328,125
Estimated value
Report date
10 Jun 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Nurix Therapeutics, Inc.

Security class
Director Stock Option (right to buy)
Shares / value
31,250
Estimated value
Report date
15 May 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Verastem, Inc.

Security class
Stock Option (right to buy)
Shares / value
12,500
Estimated value
Report date
22 May 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Anil Kapur

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .